http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5580785-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb66d9373d09efad73c142762f6dfb00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-20
filingDate 2004-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2db0c4aca4bb7c070e28e9375dd9205c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c329888bf14306fa5c08bfef237eb6b
publicationDate 2005-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CO-5580785-A2
titleOfInvention CRYSTAL SODIUM SALT OF TELMISARTAN AND ITS USE AS AN ANGONOTENSIN ANTAGONIST
abstract 1.- Telmisartan crystalline sodium salt of the formula 1 characterized by a melting point of T = 245 ± 5 ° C. 2.- Telmisartan crystalline sodium salt according to claim 1, characterized in that in the radiological dust diagram it has, among others, the characteristic values d = 20.95 Å, 17.72 Å, 13.97 Å and 13.63 Å.3.- Telmisartan crystalline sodium salt according to one of claims 1 or 2, characterized in that it is presented in form of its solvates or hydrates, preferably in the form of its hydrates. 4.- Procedure for the preparation of the crystalline sodium salt of Telmisartan 1, characterized in that Telmisartan free acid is collected in a suitable solvent, this solution is then mixed with a suitable sodium salt, in which at least 1 mole of sodium salt is added per mole of Telmisartan, then the reaction mixture is heated for a period of 15 minutes to 2 hours, then the solution obtained is filtered tra and the filtrate, obtained in this way, are slowly added to an organic solvent that can be heated to a temperature> 40 ° C, parts of the solvent are distilled off eventually even during the addition of the aforementioned filtrate, then the concentrated solution , thus obtained, the Telmisartan sodium salt which crystallizes in this case is cooled and, if necessary, after washing with the organic solvent mentioned initially, it is dried.
priorityDate 2001-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504262
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23677803
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452476757
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65999

Total number of triples: 38.